Daiichi Sankyo
4 articles
Industry NewsSummit Therapeutics / AstraZeneca / Daiichi SankyoEndpoints News
Summit, AstraZeneca and Daiichi Sankyo to test ivonescimab plus Datroway, starting with Phase III in 1L TNBC
- Summit, AstraZeneca and Daiichi Sankyo announced a clinical collaboration combining ivonescimab (PD-1xVEGF bispecific) with Datroway (datopotamab deruxtecan, a TROP2-directed ADC).
- It starts with a Phase III study in first-line triple-negative breast cancer, with plans to expand to other settings including lung cancer.
- The companies will share trial costs, and each retains development and commercial rights to its own drug.
Three companies, two assets, and no one gives up rights: this is a cost-sharing structure, not a licensing deal. For Summit, pairing ivonescimab with a validated TROP2 ADC borrows AstraZeneca and Daiichi's TNBC credibility and trial muscle. For the big partners, it is a cheap hedge on the PD-1xVEGF class. I would want to see the control arm and endpoints before judging how much it de-risks.
Industry NewsMerck / Daiichi SankyoEndpoints News
Merck, Daiichi Sankyo Withdraw FDA Application for Ifinatamab Deruxtecan in Lung Cancer
- Merck & Co. and Daiichi Sankyo voluntarily withdrew their FDA BLA for ifinatamab deruxtecan, a B7-H3-targeted ADC, in previously treated ES-SCLC.
- FDA feedback indicated Phase 2 data didn't support accelerated approval, marking the alliance's second pullback for the drug after an earlier lung-toxicity-related clinical hold.
- The companies continue the Phase 3 IDeate-Lung02 confirmatory trial and other Phase 3 studies in prostate and esophageal cancer.
A second stumble for the same molecule is a real signal, but it's about ifinatamab deruxtecan's timeline, not the Merck-Daiichi deal's overall health — this alliance is bigger than one BLA. Withdrawing rather than fighting for a contested approval is the disciplined move, protecting IDeate-Lung02's confirmatory data package. But every added year gives rival B7-H3 ADC programs room to catch up.
Industry NewsAstraZeneca / Daiichi SankyoSTAT News
NHS England to Fund AstraZeneca's Enhertu After UK-US Pricing Deal
- NICE, which sets drug-funding recommendations for NHS England, will fund Enhertu (trastuzumab deruxtecan) for HER2-low metastatic or unresectable breast cancer after chemotherapy, reversing a July 2024 rejection on cost grounds.
- The reversal follows a UK-US pharmaceutical pricing deal that led NICE to raise its cost-effectiveness threshold and revise its appraisal methodology, making some costlier innovative drugs newly reimbursable.
- Enhertu, an antibody-drug conjugate co-developed by AstraZeneca and Daiichi Sankyo, has been reported in studies to meaningfully extend survival for this patient group versus chemotherapy alone, though the size of the benefit varies.
- An estimated 1,000 patients in England are expected to gain access, with treatment available within days of the decision.
NICE just permanently loosened its willingness-to-pay bar — as a negotiated line item in a bilateral trade deal, not a one-off cost-effectiveness review. That's the story here, not the roughly 1,000 patients gaining access: expect other governments squeezed between fiscal discipline and access pressure, and other pharma negotiators facing NICE, to point to this precedent. For AstraZeneca and Daiichi Sankyo, it de-risks Enhertu's ex-US rollout playbook: reimbursement fights in other cost-constrained markets (Canada, Australia, parts of Europe) just got a stronger comparator to cite. More broadly, this nudges the ceiling on what NICE will pay for high-cost ADCs and next-gen oncology assets generally, benefiting the wider oncology ADC pipeline queuing up for UK launch, not just this one drug. Watch whether AZ/Daiichi price other Enhertu indications, or future ADCs, against this new threshold.
Industry NewsAstraZeneca / Daiichi SankyoSTAT News
NHS England to Reimburse AstraZeneca's Enhertu for HER2-Low Breast Cancer After US-UK Pricing Deal
- Enhertu (trastuzumab deruxtecan), an AstraZeneca/Daiichi Sankyo HER2-targeting antibody-drug conjugate, will now be reimbursed by NHS England for HER2-low metastatic breast cancer.
- The move reverses NICE's July 2024 rejection of the drug for this indication, ending a years-long access dispute.
- It follows a new NICE agreement made possible by a broader U.S.-U.K. drug pricing deal (announced December 2025), which raised NICE's cost-effectiveness thresholds from about £20,000-£30,000 to £25,000-£35,000 per quality-adjusted life year.
- A new quality-of-life assessment methodology, published August 27, 2026, also supported the reassessment.
- About 1,000 women a year in England with HER2-low metastatic breast cancer are expected to now qualify, with studies reporting an average survival gain of roughly six months.
The science and data here are unchanged from NICE's 2024 rejection — this is a payer-economics win, not a clinical one, and it's easy to conflate the two. What actually moved was NICE's cost-effectiveness ceiling, from roughly £20-30K to £25-35K per QALY, engineered by the broader US-UK pricing deal, not new trial results. That's the real story: the first tangible commercial outcome traceable to that trade agreement, and it hands every company with a NICE-rejected asset a concrete playbook for reopening the case. Commercially, ~1,000 patients/year in England is a rounding error for AZ/Daiichi's global Enhertu franchise — the payoff is precedent, not revenue. Watch for ripple effects: rival ADCs and other HER2-low contenders now face a materially easier cost-effectiveness bar, reshaping competitive dynamics in an increasingly crowded ADC pipeline.